Podcast appearances and mentions of vincent martin

Valérie Expert et Gilles Ganzmann reçoivent Vincent Martin, Réalisateur et Sylvie Metzelard, Rédactrice en chef - 60 millions de consommateurs pour l'émission média du 28 avril.

durée : 00:11:08 - L'Avant-scène - par : Aurélie Charon - Nous avons rencontré les quatre comédiens qui partagent le rôle de Lénine dans la nouvelle création "Ici sont les dragons" d'Ariane Mnouchkine : Arman Saribekyan, Vincent Mangado, Pamela Marin Munoz, Vincent Martin. - réalisation : Alexandre Fougeron - invités : Arman Saribekyan comédien au Théâtre du Soleil; Pamela Marin Munoz comédienne au Théâtre du Soleil; Vincent Mangado comédien au Théâtre du Soleil; Vincent Martin comédien au Théâtre du Soleil

durée : 00:11:08 - L'Avant-scène - par : Aurélie Charon - Nous avons rencontré les quatre comédiens qui partagent le rôle de Lénine dans la nouvelle création "Ici sont les dragons" d'Ariane Mnouchkine : Arman Saribekyan, Vincent Mangado, Pamela Marin Munoz, Vincent Martin. - réalisation : Alexandre Fougeron - invités : Arman Saribekyan comédien au Théâtre du Soleil; Pamela Marin Munoz comédienne au Théâtre du Soleil; Vincent Mangado comédien au Théâtre du Soleil; Vincent Martin comédien au Théâtre du Soleil

L'invitée : Marie Dejoux, MCF à l'université Paris-I Le livre : Liêm Tuttle, Marie Dejoux, Pierre-Anne Forcadet, Vincent Martin, La justice de Saint Louis. Dans l'ombre du chêne, Paris, PUF, 2024. La discussion : Un livre coécrit avec des historiens du droit (1:00) Le rôle justicier de Saint Louis et son fameux chêne (6:00) Relecture d'une affaire exemplaire : … Continue reading "341. Saint Louis justicier, avec Marie Dejoux"

Dans l'épisode du jour, j'ai le plaisir d'inviter Vincent Martin, directeur business réseau chez EasyGym. On a parlé de pleins de choses passionnantes : •   Son parcours professionnel et de sa passion pour le sport,•   De management et expérience professionnelle dans le fitness,•   L'avenir du fitness et son rôle sociétal,•   Easygym, de son modèle et des projets d'expansion,•   De leadership et de culture d'entreprise,•   Et encore beaucoup d'autres choses. Je ne vous en dis pas plus et je laisse place à ma conversation avec Vincent Martin. Où retrouver Vincent Martin   •     https://www.linkedin.com/in/vincent-martin-88a014126/ Ressources •   L'art de la victoire - Autobiographie du fondateur de NIKE - https://amzn.to/444eQLy Pour aller plus loin : > Pour recevoir, chaque semaine, mes nouveaux épisodes,rejoins la communauté des 3425 professionnels : http://rb.gy/sg64v> Pour accéder à mes programmes : https://www.andypoiron.com/programmes/> Pour en savoir plus sur Andy Poiron : https://linktr.ee/andypoironHébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Today on Talking Head Pain, Joe is on location at the American Headache Society's Scottsdale Headache Symposium. He is talking to Dr. Vincent Martin, who is presenting on Ehlers-Danlos syndrome and  its effect on people living with migraine.    Among the highlights in this episode: 00:30- Joe introduces Dr. Vincent Martin, a speaker at the American Headache Society conference in Scottsdale, Arizona 00:47- Dr. Martin tells Joe about his talk on Ehlers-Danlos syndrome and its relation to migraine 01:52- Joe asks Dr. Martin how the research is helping advance care for patients Contact Our Host: Joe Coe, Director, Education and Digital Strategy at GHLF: jcoe@ghlf.org We want to hear what you think. Send your comments, or a video or audio clip of yourself, to TalkingHeadPain@GHLF.org. Catch up on all our episodes on our website or on your favorite podcast channel. To receive headache/migraine related resources, giveaways, and latest episode releases, text the word "Headache" to 1-845-285-1563 to sign up.See omnystudio.com/listener for privacy information.

Aujourd'hui, dans "Bienfait pour vous", Mélanie Gomez et Julia Vignali ouvrent le dossier santé du jour avec le Dr Jean-Marc Sène, médecin du sport et Vincent Martin, coach sportif.

durée : 00:03:15 - La nouvelle éco - France Bleu Besançon

En France, l'été a été chaud et sec. Si de nombreuses cultures ont souffert du climat, les vignes, elles, s'en sortent bien avec un millésime 2022 prometteur. Mais les vignerons ont dû avancer la date de vendanges : près de deux semaines plus tôt que les autres années, par exemple en Champagne. Résultat : il a fallu recruter en urgence et trouver de la main-d'œuvre aussi bien française qu'étrangère. Dans les vignes de Vincent Martin, les seaux débordent de raisins. « On a des belles grappes, bien noires, bien bleu foncé, chargées de jus donc ça fait plaisir à voir », dit-il, satisfait. Le vigneron a donné le coup d'envoi des vendanges en avance, deux semaines plus tôt que l'année dernière et il a donc fallu s'organiser. « On a des collègues qui comptaient sur les étudiants, mais ils vont repartir pour les études et du coup, on va se retrouver en déficit de main-d'œuvre », dit-il. Puis il ajoute : « Sur l'exploitation, j'ai besoin d'environ 18 personnes pendant 10, 12 jours. C'est vrai que la vendange est un métier physique donc c'est compliqué de recruter. Ça fait mal au dos, ça demande d'être en forme et d'être volontaire. Il y a un besoin de main-d'œuvre. » Si certains vignerons passent par des sites d'emplois, postent des annonces sur les réseaux sociaux, ou font même appel à des prestataires privés, Vincent Martin, lui, peut compter sur un réseau de travailleurs en France et à l'étranger. « On a plusieurs origines, vous avez des locaux et puis on a des gens qui viennent de Pologne », indique le vigneron. Ces travailleurs polonais, on les trouve un peu plus au loin, accroupis en plein soleil au pied des vignes. Ici pas besoin de parler français : un sécateur et une bonne condition physique font l'affaire. « On n'est pas très expérimentés, il faut bouger les feuilles et trouver l'endroit où il faut couper », explique Béata. 1 500 euros environs pour deux semaines de vendanges Elle a fait plus de 1 600 km, elle arrive de Gdynia dans le nord de la Pologne. Ici, Béata touche le Smic horaire plus une prime de productivité, soit un revenu estimé à 1 500 euros pour deux semaines de vendanges. « Chez moi en Pologne, je suis réceptionniste dans un hôtel », raconte-t-elle. « Ici en deux semaines, je vais gagner deux fois plus que mon salaire. Notre idée en venant travailler dans les vignes, c'était de gagner un peu d'argent, d'en profiter d'être en France pour aller visiter Paris, et puis de garder un peu de sous pour en ramener à la maison. » Puis Béata ajoute : « En Pologne, je connais beaucoup de gens qui aimeraient venir travailler dans les vignes. Mais il faut avoir les bonnes connexions. Moi, j'avais un ami dans les vignes, je ne l'ai pas lâché et je l'ai finalement convaincu de m'amener avec lui. (rires) Non, mais plus sérieusement, nous, on a pas peur de travailler. » Pour attirer plus de travailleurs, le département de l'Aube y va aussi son coup de pouce. Une nouvelle fois cette année, les plus modestes peuvent travailler dans les vignes tout en continuant de toucher leurs allocations.

Les sans-dents sont peut-être affreux et sales mais ils ne sont pas méchants. En marge du monde civilisé, leur tribu recycle en toute illégalité notre rebut pour s'aménager de manière farfelue un hameau de bric et de broc. La vie pourrait ainsi couler si une équipe policière ne se mettait sur leurs traces...Avec : Yolande Moreau, Gustave Kervern, François Morel, David Salles, Charles Schneider, Vincent Martin, Philippe Rigot, Soazig Ségalou“Dingue, déjanté et lumineux.” Le Canard Enchaîné“Une poésie et une créativité sans bornes.” Le Monde“Une fantaisie grinçante à l'italienne.” Lire Magazine“Une comédie décalée qui mélange les Deschiens et l'humour de Buster Keaton.” Télé LoisirsBonus :Entretien avec Pascal RabatéAudio : Français DD 5.1 - Format Cinéma :1.85DVD Pal toutes zones

durée : 00:04:40 - L'invité du 6h-9h France Bleu Besançon

Tonight's guest, Vincent Martin, couldn't sleep one night, in the summer of 1997, so he decided to go for a drive, out in the country, to a natural spring he knew about, in Kirtland, Ohio. He left home at around 10 PM that night, so by the time he decided to head home, after spending some time at the spring, it was pretty late. While he was driving home, after going a short distance from the spring, up ahead on the right side of the road, he saw a dark figure. A figure that he says was black as carbon. As he got closer to it, he saw that it looked like a crouching Werewolf. Making matters worse, his passenger window was down and it was so close to the side of the road, a passenger in his car could have been able to reach out and grabbed its muzzle. As Vince drove past it, at about 25 miles per hour, he was too terrified to swerve away from it. He was rattled to the core, but made it past the creature without any problems. Wanting to verify that his eyes weren't playing tricks on him, though, he made a loop and decided to go back... If you'd like to check out my new Bigfoot show, called My Bigfoot Sighting, here's a link to the My Bigfoot Sighting YouTube Channel…. https://www.youtube.com/channel/UC_v5B0Q81aLiatYVABOEZWw/videosTo find out how to listen to Dogman Encounters commercial-free, please visit https://DogmanEncounters.com/PodcastIf you'd like to help support the show, by buying your own Dogman Encounters t-shirt, sweatshirt, tank top, or coffee mug, please visit the Dogman Encounters Show Store, by going to https://Dogman-Encounters.MyShopify.comIf you've had a Dogman encounter and would like to speak with me about it, whether you'd like to keep your encounter confidential or be interviewed on a show, please go to https://DogmanEncounters.com and submit a report.If you've had a Sasquatch sighting and would like to be a guest on Bigfoot Eyewitness Radio, please go to https://BigfootEyewitness.com and submit a report.Thanks for listening!

Une étape à franchir si l'on veut rester compétitif, pas si complexe si l'on s'y plonge, et dont on tire rapidement des bénéfices substantiels en termes de temps, d'énergie et de coordination des différents intervenants sur un chantier. Une interview éclairante signée Michaël Dumbi et Michel Godart.

Guillaume Millet is a researcher and athlete. He has contributed immensely to our understanding of ultramarathon performance. Gui’s Twitter account : @kinesiologuiGui’s website: www.kinesiologui.comGui’s lab: Inter-university Laboratory of Human Movement Biology www.libm.fr/en and www.actifs.orgThe names of the people who have worked with Gui on ultra studies:John Temesi, Vincent Martin, Léonard Féasson, Gianluca Vernillo, Thibault Besson, Jean-Benoit Morin, Laurent Gergelé, Grégoire Millet, Marlene Giandolini, Thomas Rupp, Pierrick Arnal, Nicolas Place, Jérémy Rossi, Pierre Samozino, Francis Degache, Samuel Vergès, Philippe Gimenez, Thomas Lapole, Paul Robach, Katja Tomazin, Pascal Edouard, Frederic, Sabater Pastor, Giorgio Varesco, Jerôme Koral, Audrey Parent, Diana Rimaud, Djahid Kennouche, Nicolas Royer, Callum Brownstin, Loic Espeit, Clément Foschia, Laurent MessonnierThe presentation referenced at the beginning of the podcastInformation on coaching-www.trainright.comKoop’s Social Media-Twitter/Instagram- @jasonkoop

NUIT EUROPEENNE DES CHERCHEUR·E·S | VINCENT MARTIN | Bordeaux by 415663

NUIT EUROPEENNE DES CHERCHEUR·E·S | VINCENT MARTIN | Bordeaux by 415663

A Leaders Voice w/ Guest Vincent Martin We will be discussing many concerns including the current climate of policing, social injustices as well as Mr. Martins's wrongful incarceration and how he has been instrumental in helping others while incarcerated and since his release. Vincent Martin was born in Richmond Virginia. He is the author of " Justice Denied". Martin was wrongfully convicted, resulting in spending 41 years in prison. He found a new purpose in helping to provide vital support and services to other incarcerated people. Martin is a member of the National Action Network Richmond Chapter, and the Council for Incarcerated De-escalation Committee. Vincent Martin's life echoes encouragement for countless others, as he often says, " Thank God Almighty for a sound mind and the ability to endure." #NationalActionNetwork #Brenda #police #reform #injustice #williemartin #stormtalk365radio #aleadersvoice #Bonita https://www.facebook.com/msb.stormtalk365/ https://www.facebook.com/brenda.coles.9406 https://www.facebook.com/nationalactionnetwork Disclaimer: The views and opinions expressed in this podcast are those of the authors/owner/ guests and do not necessarily reflect the official policy or position of Storm Talk 365 Radio/ Storm Radio 24/7, any of the affiliates, sponsors or concerned parties represented by the network. Podcast content, editing, episode descriptions, and audio content are the responsibility of the podcast owner. All information, content, and music provided solely for general information, reference, and entertainment purposes only. No copyright infringements implied. **We Do Not Own The Rights To Any Music. Or The Contents of This Podcast. Used For Entertainment Purposes Only** www.stormtalk365radio.com https://www.facebook.com/stormt.../www.stormtalk365radio.com Tags: stormtalk365radio stormtalk365 leaders a leadersvoice ministry communityaction communityawareness socialissues

We are joined by one of the nicest competitive Keyforge Players I know and we talk about card quality and value. --- Send in a voice message: https://anchor.fm/kfpl/message Support this podcast: https://anchor.fm/kfpl/support

The Incompetent Crew talks viral plagues and Moses gets eaten by zombies.Works CitedBlack Death Music PartiesMike Davis, The Coronavirus Crisis is a Monster Fueled by CapitalismPandemic Fear and Literature: Observation’s From Jack London’s The Scarlet PlagueHistory of ZombiesMax BrooksContagionThe Andromeda StrainThe Omega ManVirus, Day of ResurrectionNight of the Living DeadThe Dead Don’t DieThe Girl With All The GiftsRadio PlaylistA 3 dans les WC - ContagionEnsemble Gilles Binchois & Dominique Vellard - Nes que on porroit les estoilles nombrer (Ballade)Stian Westerhus - Infectious DecayAlgiers - Plague YearsMGMT - Mystery DiseaseArve Henriksen - Patient ZeroUltrademon - March 29 - Viral HostYapoos - ヴィールス (Virusu)Boys Age - Plague CirculationGil Mellé - Wildfire (2:46)Myelin Sheaths - Everything Is Contagious (2:48)Sufjan Stevens - They Are Night Zombies!! They Are Neighbors!! They Have Come Back from the Dead!! Ahhhh! (5:09)Pintandwefall - Zombie (2:20)Vincent Martin & His Bahamians - Zombie Jamboree (3:15)Baloji - Glossine (Zombie) (3:46)Roky Erickson and The Aliens - I Walked With A Zombie (2:49)Radiation City - Zombies (3:42)Fela Kuti - Zombie (12:26)

In this podcast, Vincent Martin, MD, from the University of Cincinnati, defines migraine triggers, discusses the pathophysiology of migraine triggers, and explains how to clinically manage migraine triggers. More at: www.consultant360.com/neurology.

  Welcome to another episode of Biotechnology Focus radio! I am your host – Michelle Currie – here to give you the rundown on what is happening in biotech across the country from coast to coast. There have been some interesting developments in the last couple weeks that are changing the scope of the life sciences industry. Some of which I get the pleasure to share with you today. As a first for Canada, Concordia University now houses a facility that will change how synthetic biology research will be conducted; Bioasis Technologies’ promising drug development may have found a way to cross the blood-brain barrier; the Centre for Commercialization of Antibodies and Biologics invests in ImmunoBiochem to advance their therapeutic candidate; and the Canadian government, as well as other investors, allocate $8.8 million to three projects in Ontario.   Keep on listening to find out more details!  +++++  A new facility at Concordia is about to change history. It will house robots that will bring a whole new concept of speed and scale to synthetic biology research.  The Genome Foundry is the first Canadian laboratory of its kind, and amongst only a handful at leading institutions around the world. By automating notoriously labour-intensive lab work, it will eliminate bottlenecks in a rapidly evolving field where the design principles of engineering fuse with the tools of biology to create meaningful synthetic biological systems.  Christophe Guy, vice-president of Research and Graduate Studies at Concordia says that the Genome Foundry solidifies Concordia’s position as the Canadian leader in synthetic biology research and will enable their scientists to work at the cutting-edge while facilitating partnerships with other institutions. Given that Concordia researchers are already engaged internationally in defining the future of this field, they are eager to witness how this new facility will support the transformative work being done at the university.  At the moment, much of the lab work done by synthetic biologists involves moving and combining small amounts of liquids and cells. The Genome Foundry’s robotics will allow for speed and absolute precision, thus greatly increasing the variety and number of experiments that can be completed, and the accuracy with which they can be reproduced.  The Genome Foundry was established with funds from the Canada Foundation for Innovation and the government of Quebec and is part of Concordia’s synthetic biology hub along with the Centre for Applied Synthetic Biology (CASB), the SynBioApps NSERC CREATE program and the soon-to-be-inaugurated District 3 Innovation Centre science hub.  Vincent Martin, co-director of the Centre for Applied Synthetic Biology says that they are thrilled to open the doors of our Genome Foundry. That this is a monumental addition to Canada’s synthetic biology ecosystem. It empowers researchers to navigate uncharted waters alongside international colleagues, and to incubate the future leaders of the field.  The Centre for Applied Synthetic Biology aims to develop high-value applications in human health, agriculture, chemicals and environmental technologies. It also provides a broad range of unique opportunities — such as the recently announced NSERC CREATE SynBioApps program — for training leading experts in the field.  Launching this technology platform also marks Canada’s participation in the next generation of synthetic biology, with Concordia now engaged in directing how this infrastructure will be developed and used on a global scale.  This facility will have real world, potential life-saving capabilities that deliver an innovative scientific approach to create genetic blueprints for individuals, bring more knowledge to researchers on a faster scale, and help physicians diagnose, treat and prevent their patients from contracting future diseases.  +++++  With neurological diseases predicted to rise exponentially across the globe, whether resulting from the extension of life expectancy or aging populations, more novel solutions are necessary so that health care can stay ahead of the game.  Neurological diseases, disorders and injuries – such as Alzheimer’s disease, amyotrophic lateral sclerosis, multiple sclerosis, brain tumours, and Parkinson’s disease – are some of the leading causes of disability amongst the Canadian population that take a toll not only on the patient and the Canadian health care system, but also have a significant economic impact.  To date, these neurological diseases and disorders have been largely incurable and tend to worsen over time, typically involving invasive procedures by scientists and researchers as they attempt to penetrate the blood-brain barrier. Remarkable as the blood-brain barrier is to neuroscience, it is extremely fickle and highly selective, restricting the paracellular diffusion of water-soluble substances from the blood to the brain. Despite it being nature’s evolutionary way of protecting humans’ greatest asset, it does not come without its faults. Its defensive properties impede the way for medicinal compounds to penetrate the barrier and deliver the potential life-saving properties to their destination point.  Statistics have shown that 1 in 6 will acquire a neurological disease, totalling about 1.25 billion people worldwide. It is for this reason Canadian company Bioasis Technologies Inc. is determined to deliver effective treatments to patients who suffer from one of these diseases.  Vancouver-founded Bioasis has undertaken this challenge by focusing on a single goal: revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain. They have developed and are in the process of commercializing their proprietary brain delivery technology, the xB3 platform, to make life-saving drugs brain-penetrant and deliver those therapies at a therapeutically relevant dose.  Inception of the company began back in 2007 when researchers discovered an extremely large peptide that was capable of crossing the blood-brain barrier with a substantial amount of cargo. The team did a couple of experiments with Doxorubicin in mice models with cancer that positively showed higher survival rates and became the first proof of concept. The also acquired Trastuzumab data whereby they transferred Herceptin across the blood-brain barrier in sufficient quantities to reduce the number of tumours.  Although researchers have been speculating about less invasive methods that will penetrate the barrier, Mark Day, the president and chief executive officer of Bioasis, comments that the key thing if you have brain cancer is that the only therapeutic benefit will come from a direct infusion into the brain – like drilling a hole in the head – and while some people are trying to inject into the spine and pump it into the central nervous system, none of it has worked. The brain methods do work, so there is at least some data if you inject it that you can get it approved for efficacy for small groups of patients.  Recently, MedImmune, a wholly-owned subsidiary of AstraZeneca, did an independent validation of Bioasis’ xB3 platform technology that transpired incredible results. The study found that the xB3 fusion protein maintained the systemic pharmacokinetics of its payload and had significantly improved and sustained brain exposure of the payload molecule. It provided evidence that Bioasis’ platform technology was recombinant and chemically conjugated drugs across the blood-brain barrier to increase brain exposure.  These data and validation from MedImmune provide promising results that it will work in a phase 1 study. Bioasis figured out that once they attached Trastuzumab to 12 active amino acids (peptide 12aa), 10 times the amount of the drug passed through the blood-brain barrier. Mark Day adds: “What is really important is that once the drug is in the brain it hits the tumour. Looking at these results you can see that there are significant therapeutic doses in the brain and in controlled regions. This shows us that the drug gets into the brain, it gets to the site of action, and binds to those specifically where there are HER2 positive cells.”  Bioasis has four main programs:  xB3-001: Brain Metastases, which is the most common form of brain cancer in adults and is often fatal due to anti-cancer drugs being unable to pass the blood-brain barrier, and is also the program that will progress first to human trials in 2019;  xB3-002: Glioblastoma, one of the most aggressive cancers that originates within the brain, with 80 per cent of diagnosed primary malignant brain tumours as malignant gliomas. It is considered the deadliest form of brain cancer due to its high infiltration of surrounding brain tissue. This program is being done in collaboration with Minerva in Copenhagen;  xB3-007: Neurodegenerative diseases, which entail a progressive loss of function by the neurons in the brain and in being diagnosed at an alarming rate partly due to an aging population; and  xB3-008: Lysosomal storage diseases, which are inherited metabolic diseases that are characterized by an abnormal build-up of various toxic materials in the body’s cells as a result of enzyme deficiencies.  If the xB3-001 and xB3-002 programs are successful, it would be the first time in human history that medicine for cancer has been properly received into the brain without having to drill into the patient’s head. This will be a breakthrough in science and open the doors to a floodgate of scientific possibilities.  Bioasis’ technology platform has been so efficacious that there simply have not been any competitors that have been able to keep up. The receptor with which they work with is ubiquitous to the blood-brain barrier walls, providing more possible passageways for medicine to penetrate through. This receptor, even in its natural form, is critical in cleaning out harmful tissues in the brain like Alzheimer’s disease for example and is necessary to maintain brain integrity.   Mark Day adds that the other thing that differentiates them is how they develop drugs. They know that if you engage the target and prove that the target engagement drives biologic effect – to schizophrenia that would be a lowering of dopamine – then you have a good sense of patient population. So, for some of these diseases, there is a very strong genetic basis to them and subsequent diseases that gives them the mechanism to recruit the patient who is most likely to benefit from the medicine in the first tranche.  The proof of principal in the first point, get the proof of concept, on the back of a positive proof of concept then you would go earlier into the diseases. That’s what they can do with our last two neurodegeneration products. Basically, they go into a smaller niche indication, get the proof of concept and then expand it into other disease areas. That’s been the strategy.  With recent editions to their scientific advisory board and looking ahead to put them in the best financial position for Nasdaq, the future looks promising for this biotechnology company. Penetrating the blood-brain barrier has been an arduous task, but if Bioasis is successful, their technology will revolutionize the treatment for neurodegenerative diseases and brain tumours, potentially slowing the progression of disease, and maybe someday offer a cure.  +++++  The Centre for the Commercialization of Antibodies and Biologics (or CCAB) provides a new investment to help advance ImmunoBiochem’s novel breast cancer therapeutic candidate one step closer to the clinic. The agreement marks a first for CCAB as part of its new business strategy, which aims to attract investment to create successful life sciences companies in Canada. CCAB will develop ImmunoBiochem’s lead candidate towards regulatory filings, and merge their business acumen with its research and technical expertise to support the co-development of new biological therapeutics.  CCAB CEO Robert Verhagen says that today’s announcement marks the beginning of a very exciting period of growth. The agreement with ImmunoBiochem is a natural extension of an already fruitful partnership and that they are looking forward to helping the company get to the next crucial stage in the development of this promising anti-cancer therapy. As CCAB continues to expand its mission in this space, they plan on establishing similar partnerships with other emerging companies in the near future.  ImmunoBiochem is developing novel potentiated biologics to treat triple-negative breast cancer (TNBC), an aggressive form of breast cancer for which there are currently no targeted biological treatment options. Earlier this quarter, ImmunoBiochem secured an additional private investment to support its pipeline and entered into a license agreement with the University of Toronto for novel therapeutic antibodies.  ImmunoBiochem’s CEO Dr. Anton Neschadim says that ImmunoBiochem’s highest priority is to make new treatment options available for patients with this difficult-to-treat breast cancer. They have made significant progress and have validated their approach in vivo. CCAB has been tremendously supportive of their work and they are excited that this new agreement will help them advance their lead candidate even further.   Breast cancer is the most common cancer among Canadian women and is the second leading cause of death from cancer. In 2017, 26,300 women were diagnosed with breast cancer and 5,000 women died from the disease. Triple-negative breast cancer accounts for up to 20 per cent of breast cancers and is one of the most heterogeneous diseases, comprising multiple breast cancer sub-types. Consequently, even highly promising treatments that are in late stages of the clinical pipeline are likely to only address the needs of a partial number of triple-negative breast cancer patients. ImmunoBiochem has developed therapeutic candidates that aim to close on this gap by overcoming treatment challenges associated with tumor heterogeneity.  Much of biological therapeutics distinguish cancer cells from normal cells based on proteins differentially expressed on their surface. In solid tumours, most such targets are heterogeneously expressed, impeding complete responses and driving resistance and relapses. ImmunoBiochem is focusing instead on selective targets in the tumour microenvironment that are broadly present and interact with all cells in a tumour, including tumour-supporting stroma. ImmunoBiochem has shown that this approach could be more effective and safer than conventional surface-targeted therapeutics.  This agreement between the two companies has the potential to lead to viable therapeutics that are sorely needed, especially for cancers that have a high rate of morbidity and mortality.  +++++  Genome Canada announces federal funding for seven new projects under the Genome Canada’s Genomic Applications Partnership Program (GAPP), three of which hail from Ontario. This will be driving $2.9 million of federal funding into the province and an additional $5.9 million from investments in the industry, government, and funding partners. For a total of $8.8 million, this could heed rewarding results.  The announcement was made by the Minister of Science and Minister of Sport and Persons with Disabilities. The Honourable Kirsty Duncan, at the Vineland Research and Innovation Centre.  Vineland is partnering with a team of University of Toronto researchers to develop genomics-based technologies that will induce broad-spectrum disease resistance in greenhouse vegetables, allowing new varieties of vegetables to thrive and reducing waste. This will give growers across Ontario and Canada a competitive advantage in a national industry that already generates more than $1 billion annually from retail sales and exports.  In another Genomic Applications Partnership Program project, researchers at McMaster University are partnered with Hamilton-based start-up Adapsyn Bioscience Incorporated to use its proprietary technology platform that combines genomic and metabolomic data with artificial intelligence and machine learning to redefine and accelerate drug discovery for novel treatments of a wide spectrum of diseases. This partnership secured significant foreign and domestic investment and is creating new high-tech jobs in Ontario.  The third Ontario-based Genomic Applications Partnership Program project announced brings together researchers at the Sunnybrook Research Institute and the University of Toronto with Canadian start-up Fusion Genomics to further develop novel infectious disease surveillance tools. Their technology is unique in its ability to detect and genetically characterize infectious viral pathogens through bioaerosols to serve as an early warning for disease outbreaks in both humans and agricultural animals. The development of this pre-emergence environmental detection technology will drive a paradigm shift in public health and animal welfare by offering complete genomic data to anticipate outbreaks, inform disease transmission dynamics and enable vaccine design and production.  Genomic Applications Partnership Program is a program that partners researchers with companies and other end-users who will apply their innovations with the goal of increasing and accelerating the positive social and economic impact of Ontario’s and Canada’s genomics R&D capacity. Since 2013, approximately $86.1 million, including co-funding has been invested in 23 Ontario-based Genomic Applications Partnership Program projects, fuelling innovations, spurring job creation and attracting foreign investment in Ontario’s health, agriculture & agri-food, fisheries, environment and natural resource sectors.  In such an emerging industry, there is nothing better than seeing companies and research succeed. With these recent investments, there is high hope that we will see encouraging results in the future.  +++++  Well that wraps up another episode of Biotechnology Focus radio! Thanks for listening! If you have a story or a story idea, feel free to contact me at press@promotivemedia.ca. Until the next time, from my desk to yours – this is Michelle Currie.

País Francia Director David Oelhoffen Guion David Oelhoffen (Relato: Albert Camus) Música Warren Ellis, Nick Cave Fotografía Guillaume Deffontaines Reparto Viggo Mortensen, Reda Kateb, Djemel Barek, Vincent Martin, Nicolas Giraud, Jean-Jérôme Esposito, Hatim Sadiki, Yann Goven, Antoine Régent, Sonia Amori, Antoine Laurent, Ángela Molina Sinopsis Argelia, 1954. En medio del duro invierno, Daru (Viggo Mortensen), un profesor francés, acepta de mala gana escoltar a Mohamed (Reda Kateb), un hombre acusado de asesinato, a través de las montañas Atlas para que se enfrente a juicio. Perseguidos por hombres que reclaman la ley de la sangre y por colonos revanchistas, los dos hombres se rebelan. Juntos lucharán para recuperar la libertad.

Artists Adnan Naseem Khan and Vincent Martin discuss their audio visual journeys into Astral Hawk Interactive and give us a sneak peak into their new case study called Augury- A Digital Mythos.

In this first episode of TARGET: Zero Hunger, we explore FAO’s work in emergencies and what it takes to help families produce food in some of the most difficult crisis regions in the world.  FAO Communications officer Like Visser takes us deep into the Nyal region of South Sudan, where people have been struggling with severe food insecurity for months; and we speak to Etienne Peterschmitt, who leads FAO’s emergency response to the crisis in Yemen, about the day-to-day realities of supporting food production in an active conflict zone. We also talk to Toby Lanzer, the UN’s Regional Humanitarian Coordinator for the Sahel, and with Vincent Martin, Coordinator of FAO’s resilience team in West Africa and the Sahel, about what it's like to build an emergency response plan for a region of 150 million people. Along the way, they help answer why investing in agriculture in crisis regions is not only key to saving the lives and livelihoods of people facing hunger, but for securing a decent future for generation of young people growing up in rural areas.

In this month's Cell Podcast, we learn about the promises and potential perils of synthetic biology, with Vincent Martin and Tania Bubela (0:00), why sirtuin inhibitors may bring a cure for CML a step closer, with Ravi Bhatia (9:44), and how platelet producing cells avoid the pinch to become polyploid, with Diane Krause (14:56). Plus, sample a selection of the hottest new papers from Cell Press (23:14).

Greg Sylvander, Sean Rochester & Bryan Fonseca jump on live after watching with fans on Playback.tv/5RSN to talk about the Heat's dominant victory in Miami to go up 3-0 on the Celtics.Sponsors: InsuranceByLinnette.com, SmartyPantzMarketing.com, BettorEdge (5RSN)Our Sponsors:* Check out PrizePicks and use my code fiveonthefloor for a great deal: https://www.prizepicks.com* Check out Steel Tie Spirits: https://steeltiespirits.com/* Check out Uncommon Goods and use my code FIVEONTHEFLOOR for a great deal: www.uncommongoods.comAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy